EMA Backs Preventive Therapy for Stage 3 Type 1 Diabetes

The European Medicines Agency (EMA) has recommended granting marketing authorization for Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged 8 years and older with stage 2 T1D.  Teizeild was granted entry into the PRIME medicine scheme in 2019…